●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial.
Form 8-K INTERPACE BIOSCIENCES, For: Nov 08 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Interpace Biosciences (IDXG) Tops Q2 EPS by 17c streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Veracyte's products are marketed as LDTs and are not approved by the FDA. Click here to read more to know the reasons why VCYT stock has a Hold rating.